A study of patients with incurable lung cancer suggests that volatile organic compounds may be useful, objective indicators of how soon someone may die.
A real-world evidence study shows an advantage in median overall survival among non-small cell lung cancer patients who were treated with second-line immunotherapy compared to those treated with chemotherapy. Multivariable analysis showed healthcare resource utilization was comparable.
Treatments aimed at certain mutations have proliferated and moved upstream to earlier-stage lung cancers. But there are many questions about insurance coverage and which tests to use to identify the biomarkers that help guide treatment.